Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients.
GP88
bladder cancer
immune cells
lymph node stage
prognosis
tumor cells
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
08
06
2021
revised:
12
07
2021
accepted:
14
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74;
Identifiants
pubmed: 34359965
pii: cells10071796
doi: 10.3390/cells10071796
pmc: PMC8306318
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Rudolf und Irmgard Kleinknecht-Stiftung
ID : none
Organisme : Johannes und Frieda Marohn-Stiftung
ID : none
Organisme : Wilhelm Sander-Stiftung
ID : 2015.171.1
Organisme : Deutsche Gesellschaft für Urologie
ID : 14-07-11-1-Huppert
Organisme : Elan-Fund
ID : 18-08-18-1-Sikic
Références
PLoS One. 2012;7(6):e39880
pubmed: 22761921
Eur Urol. 2014 Dec;66(6):1078-91
pubmed: 25151017
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401585
Cancer. 2000 May 15;88(10):2326-32
pubmed: 10820355
Hum Pathol. 2018 May;75:116-124
pubmed: 29452214
Oncoimmunology. 2021 Feb 17;10(1):1888488
pubmed: 33659099
Zhonghua Yi Xue Za Zhi. 2006 Oct 10;86(37):2611-4
pubmed: 17198586
Nat Med. 2003 Feb;9(2):225-9
pubmed: 12524533
J Mol Med (Berl). 2003 Oct;81(10):600-12
pubmed: 12928786
Hum Pathol. 2014 Sep;45(9):1893-9
pubmed: 25033727
Cytokine. 2018 Jan;101:48-55
pubmed: 27527809
Am J Pathol. 2011 Jan;178(1):284-95
pubmed: 21224065
Urol Int. 2015;95(1):56-64
pubmed: 25662337
Cancer Immunol Res. 2019 Jun;7(6):923-938
pubmed: 30988029
Biochem Biophys Res Commun. 1990 Dec 31;173(3):1161-8
pubmed: 2268320
Oncoimmunology. 2020 Apr 10;9(1):1747332
pubmed: 32313725
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Cancers (Basel). 2020 May 15;12(5):
pubmed: 32429318
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMC Gastroenterol. 2011 May 26;11:63
pubmed: 21612671
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Cancer Res. 2006 Jul 15;66(14):7103-10
pubmed: 16849556
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Gynecol Oncol. 2011 Jan;120(1):5-10
pubmed: 20950846
Cancers (Basel). 2019 Dec 16;11(12):
pubmed: 31888257
Matrix Biol. 2020 Nov;93:10-24
pubmed: 32417448
Tissue Antigens. 2007 Jul;70(1):1-11
pubmed: 17559575
J Atheroscler Thromb. 2010 Jun 30;17(6):568-77
pubmed: 20215705
Cancer Biomark. 2010;7(3):163-70
pubmed: 21263192
Oncotarget. 2016 Jun 28;7(26):39980-39995
pubmed: 27220888
Cell. 2002 Dec 13;111(6):867-78
pubmed: 12526812
Eur Urol. 2019 Jul;76(1):59-68
pubmed: 30712971
Pharmacol Ther. 2012 Jan;133(1):124-32
pubmed: 22008260
Immunity. 2011 Apr 22;34(4):505-13
pubmed: 21497117
Rinsho Byori. 2016 Nov;64(11):1296-1309
pubmed: 30695312
Oncotarget. 2018 Feb 19;9(19):15001-15014
pubmed: 29599921
Front Immunol. 2018 Mar 12;9:444
pubmed: 29593717
Drug Discov Today. 2017 Oct;22(10):1557-1564
pubmed: 28651064
Cancer Res. 2021 Mar 15;81(6):1552-1566
pubmed: 33472889
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Carcinogenesis. 2009 May;30(5):861-8
pubmed: 19237611
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Front Endocrinol (Lausanne). 2016 Jul 27;7:100
pubmed: 27512385
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Cancer Immunol Res. 2015 Jan;3(1):1-11
pubmed: 25568067
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Cancer Treat Rev. 2017 Mar;54:58-67
pubmed: 28214651
Pathol Oncol Res. 2020 Jan;26(1):397-404
pubmed: 30378010
J Leukoc Biol. 2013 Feb;93(2):199-208
pubmed: 23089745
Breast Cancer Res Treat. 2021 Apr;186(3):637-653
pubmed: 33616772
J Pathol Clin Res. 2017 Jan 13;3(1):58-70
pubmed: 28138402
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251
Clin Chim Acta. 2017 Oct;473:139-146
pubmed: 28823651
Hum Pathol. 2003 Nov;34(11):1148-54
pubmed: 14652816
J Immunother Cancer. 2020 May;8(1):
pubmed: 32448798
Breast Cancer Res. 2012 Feb 08;14(1):R26
pubmed: 22316048
Cancer Res. 2002 Oct 1;62(19):5590-6
pubmed: 12359772